207_Combined course Presentations

Extended adjuvant therapy

Intention-to-treat population

97.8%

100

93.9%

2.3%

95.6%

90

91.6%

80

70

P-value = 0.009 HR (95% CI) = 0.67 (0.50–0.91)

60

Disease-free survival (%)

Neratinib Placebo

50

0

15

3

0

6

9

12

18

21

24

Months after randomization

No. at risk Neratinib Placebo

1420 1420

1260 1324

1229 1292

1189 1243

1108 1163

1033 1090

662 704

1291 1367

1150 1209

Chan et al. Lancet Oncol 2016 32